Contact information
Sarah Kelly
MSc
Clinical Programme Director (Global)
Providing strategic and operational leadership for a global clinical research portfolio focused on vaccine-preventable diseases.
Providing strategic and operational leadership for an international clinical research portfolio focused on vaccine-preventable diseases. Responsibilities include programme planning, implementation, delivery, and governance, as well as contributions to protocol development across multiple studies. A registered nurse with a background in emergency medicine, with extensive field and operational experience through work with MERLIN in the Democratic Republic of Congo and Médecins Sans Frontières in West Africa. Since joining the Oxford Vaccine Group in 2006, has supported a wide range of industry and academic trials across the UK, Southeast Asia, Africa, and Latin America, and continues to advise and support clinical teams globally.
Recent publications
-
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
Qadri F. et al, (2024), Lancet, 404, 1419 - 1429
-
Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage, and carriage density in Nepalese children after PCV10 introduction: A pre-post comparison study.
Kandasamy R. et al, (2024), Vaccine, 42, 4066 - 4071
-
Evaluation of Acute and Convalescent Antibody Concentration Against Pneumococcal Capsular Polysaccharides for the Diagnosis of Pneumococcal Infection in Children with Community-Acquired Pneumonia
Carter MJ. et al, (2024), Pediatric Infectious Disease Journal, 43, E67 - E70
-
Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal.
Shakya M. et al, (2019), N Engl J Med, 381, 2209 - 2218